<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Reports of Biochemistry and Molecular Biology</title>
<title_fa></title_fa>
<short_title>rbmb.net</short_title>
<subject>Basic Sciences</subject>
<web_url>http://rbmb.net</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2322-3480</journal_id_issn>
<journal_id_issn_online>2322-3480</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/rbmb</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1400</year>
	<month>10</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2022</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<volume>10</volume>
<number>4</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>PI3K Inhibition Sensitize the Cisplatin-resistant Human Ovarian Cancer Cell OVCAR3 by Induction of Oxidative Stress</title>
	<subject_fa>بیوشیمی</subject_fa>
	<subject>Biochemistry</subject>
	<content_type_fa>مقالات اصلی</content_type_fa>
	<content_type>Original Article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;strong&gt;&lt;em&gt;Background:&lt;/em&gt;&lt;/strong&gt; This study evaluates the effect of simultaneous AKT inhibition and cisplatin therapy in&amp;nbsp;changes of Reactive Oxygen Species (ROS) production, apoptosis induction, and cell survival in cisplatinresistant&amp;nbsp;OVCAR3 cell.&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;&lt;em&gt;Methods:&lt;/em&gt;&lt;/strong&gt; OVCAR3 cancer cells were treated with cisplatin, Ly 294002 (LY), and cisplatin+Ly to&amp;nbsp;investigate the cytotoxicity effect of the mentioned groups via MTT assay. Then, DCFH-DA (2&amp;prime;, 7&amp;prime;-&amp;nbsp;dichlorodihydro fluorescein diacetate) assay kit is used to assess the potential of treated groups in&amp;nbsp;intracellular ROS generation. Protein expression levels of caspase-3, cleaved caspase 3, PI3K, Akt, p-Akt,&amp;nbsp;XIAP, and Survivin are estimated through immunoblotting assay in all three experimental groups.&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;&lt;em&gt;Results:&lt;/em&gt;&lt;/strong&gt; The results showed that all three treated groups, including cisplatin and Ly alone and coadministration&amp;nbsp;of cisplatin+Ly, could reduce the cell vitality of OVCAR3 cancer cells, induced intracellular&amp;nbsp;production of ROS and increased the expression level of activated caspase 3 and Akt protein, whereas downregulated&amp;nbsp;the phosphorylation of Akt protein. However, the effect of combination therapy was more tangible&amp;nbsp;compared to single therapy and control groups. In contrast, the expression amount of XIAP, Survivin, and&amp;nbsp;PI3K did not show detectable changes in comparison with the control group.&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;&lt;em&gt;Conclusions:&lt;/em&gt;&lt;/strong&gt; The results showed that the AKT inhibition by Ly could sensitize the OVCAR3 cancer&amp;nbsp;cells to the cisplatin and lower the effective dose of cisplatin through hyperactivation of oxidative stress.&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Caspase-3, Cisplatin, Ovarian cancer, PI3K/Akt signaling.</keyword>
	<start_page>675</start_page>
	<end_page>685</end_page>
	<web_url>http://rbmb.net/browse.php?a_code=A-10-233-4&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>SAHAR</first_name>
	<middle_name></middle_name>
	<last_name>Baghal-Sadriforoush</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460012481</code>
	<orcid>100319475328460012481</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of biology, Science and Research branch, Islamic Azad University, Tehran, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Morteza</first_name>
	<middle_name></middle_name>
	<last_name>Bagheri</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>mortezabagheri@umsu.ac.ir.</email>
	<code>100319475328460012482</code>
	<orcid>100319475328460012482</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Isa </first_name>
	<middle_name></middle_name>
	<last_name>Abdi Rad</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460012483</code>
	<orcid>100319475328460012483</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Fattah</first_name>
	<middle_name></middle_name>
	<last_name>Sotoodeh Nejadnematalahi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460012484</code>
	<orcid>100319475328460012484</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of biology, Science and Research branch, Islamic Azad University, Tehran, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
